Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Project aim is to quantify the influence of a severe therapy-refractory heart failure caused by ischemic or dilative myocardiopathy on the function of the diaphragm, its molecular biological parameters and on the M. vastus lateralis. The control group consists of patients with coronary artery disease (CAD) and normal left ventricular ejection fraction indicated for coronary artery bypass graft surgery (CABG) Differences in the geneses of heart failure (ischemic vs. dilative cardiomyopathy) will be evaluated during analysis. The ubiquitin-proteasome signaling pathway is considered as a central issue for the mechanism of the analyses muscle catabolism.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Patients (age 40 - 70 years) with severe therapy-refractory heart failure caused by ischemic or dilatative myocardiopathy with indication for left ventricular assist device (LVAD) therapy |
| |
| Arm 2 | Patients (age 40-70 years) with the indication for elective bypass surgery and normal left ventricular function (EF>50%) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Biopsy of the diaphragmatic muscle | Other |
| ||
| Skeletal muscle biopsy |
| Measure | Description | Time Frame |
|---|---|---|
| Expression of catabolic E3 ligase Muscle ring finger 1 (MuRF1) | at the time of index procedure (biopsy) |
| Measure | Description | Time Frame |
|---|---|---|
| in vitro measurement of the muscle protein - poly ubiquitination of Proteins | at the time of index procedure (biopsy) | |
| in vitro measurement of the muscle protein - the proteasome activity | at the time of index procedure (biopsy) |
Not provided
Inclusion Criteria:
inclusion criteria Group A:
inclusion criteria Group B:
inclusion criteria Group C:
Exclusion Criteria:
Not provided
Not provided
Patients with severe therapy-refractory heart failure
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Heart Center Leipzig | Leipzig | Germany |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 33535772 | Derived | Mangner N, Garbade J, Heyne E, van den Berg M, Winzer EB, Hommel J, Sandri M, Jozwiak-Nozdrzykowska J, Meyer AL, Lehmann S, Schmitz C, Malfatti E, Schwarzer M, Ottenheijm CAC, Bowen TS, Linke A, Adams V. Molecular Mechanisms of Diaphragm Myopathy in Humans With Severe Heart Failure. Circ Res. 2021 Mar 19;128(6):706-719. doi: 10.1161/CIRCRESAHA.120.318060. Epub 2021 Feb 4. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Other |
|
| in vitro measurement of the muscle protein - fiber typing in the muscle samples | at the time of index procedure (biopsy) |
| in vitro measurement of the force development of skinned muscle fibers | at the time of index procedure (biopsy) |
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided